Ea3132- Phase II Randomized Trial Of Radiotherapy With Or Without Cisplatin For Surgically Resected Squamous Cell Carcinoma Of The Head And Neck (Scchn) With Tp53 Sequencing
Posted Date: Oct 26, 2020
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The purpose of this study is to evaluate the disease-free survival (DFS) of patients with stage III-IV squamous cell carcinoma of the head and neck (SCCHN) and disruptive p53 mutations after primary surgical resection followed by postoperative radiotherapy (PORT) alone or PORT with concurrent cisplatin
Criteria:
To Be Eligible: Must Have Pathologically Proven Diagnosis Of Squamous Cell Carcinoma, Ecog 0-1, Total Resection Of Tumor, Adequate Organ Function, No Previous Radiation To The Head And Neck, No Recurrent Disease, No Intercurrent Illness That Interferes With Protocol Therapy
Keywords:
Scchn, Head And Neck Cancer
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com